Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer
MetadataShow full item record
Altmetrics Handle Statistics
Altmetrics DOI Statistics
Emerging data demonstrate homologous recombination (HR) defects in castration-resistant prostate cancers, rendering these tumours sensitive to PARP inhibition. Here we demonstrate a direct requirement for the androgen receptor (AR) to maintain HR gene expression and HR activity in prostate cancer. We show that PARP-mediated repair pathways are upregulated in prostate cancer following androgen-deprivation therapy (ADT). Furthermore, upregulation of PARP activity is essential for the survival of prostate cancer cells and we demonstrate a synthetic lethality between ADT and PARP inhibition in vivo. Our data suggest that ADT can functionally impair HR prior to the development of castration resistance and that, this potentially could be exploited therapeutically using PARP inhibitors in combination with androgen-deprivation therapy upfront in advanced or high-risk prostate cancer.Tumours with homologous recombination (HR) defects become sensitive to PARPi. Here, the authors show that androgen receptor (AR) regulates HR and AR inhibition activates the PARP pathway in vivo, thus inhibition of both AR and PARP is required for effective treatment of high risk prostate cancer.
Asim , M , Tarish , F , Zecchini , H I , Sanjiv , K , Gelali , E , Massie , C E , Baridi , A , Warren , A Y , Zhao , W , Ogris , C , McDuffus , L-A , Mascalchi , P , Shaw , G , Dev , H , Wadhwa , K , Wijnhoven , P , Forment , J V , Lyons , S R , Lynch , A G , O'Neill , C , Zecchini , V R , Rennie , P S , Baniahmad , A , Tavaré , S , Mills , I G , Galanty , Y , Crosetto , N , Schultz , N , Neal , D & Helleday , T 2017 , ' Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer ' , Nature Communications , vol. 8 , 374 . https://doi.org/10.1038/s41467-017-00393-y
© 2017 The Authors. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
DescriptionThis study was supported by the National Cancer Research Institute (National Institute of Health Research (NIHR) Collaborative Study: ‘Prostate Cancer: Mechanisms of Progression and Treatment (PROMPT)” (grant G0500966/75466). This work was funded by a Cancer Research UK program grant (D.N.), the Swedish Research Council (T.H.), AFA insurance (T.H.), Swedish Cancer Society (T.H.), the Swedish Pain Relief Foundation (T.H.), the Torsten and Ragnar Söderberg Foundation (T.H.), AstraZeneca (T.H.) Centre for Clinical Research (CKF) (F.T.), the Västmanland Research Foundation for Cancer in Vasteras (F.T.), the Henning and Ida Persson Research Foundation (F.T.).
Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.